2026 TIDES Oligonucleotide & Peptide Therapeutics
May 11-14, 2026
Hynes Convention Center
Boston, Massachusetts
Visit us at BOOTH #130
Meet BioAgilytix at TIDES USA 2026 to discuss bioanalytical and CMC analytical strategies designed to support complex therapeutics from early development through commercialization.
BioAgilytix is Supporting the Work Behind Complex Therapeutics
As programs move from discovery into development and manufacturing, the analytical strategy behind them becomes increasingly critical. Decisions made early can impact timelines, data quality, and regulatory readiness downstream.
That’s where having the right partner matters.
BioAgilytix works alongside teams developing oligonucleotide, peptide, and mRNA therapeutics to build analytical approaches that align with both the science and the stage of development. From early method development through clinical testing and CMC support, our goal is to help bring clarity to complex programs and generate data you can move forward with confidence
When Complexity Increases, Your Analytical Strategy Has to Keep Up
BioAgilytix brings together bioanalytical and CMC analytical expertise under one global framework, helping sponsors reduce handoffs and maintain consistency across development stages.
Our team’s support:
- Global bioanalytical and CMC analytical programs
- Integrated LC/MS and ligand binding assay strategies
- RNA, peptide, and complex modality expertise
- Method development, validation, and transfer
- QC release and stability testing
With laboratories across the United States, Europe, and Australia, BioAgilytix delivers scalable capacity with harmonized processes and consistent quality.
Schedule a meeting with our experts on site
Learn how the combination of world-class scientific expertise, outstanding project management, and key regulatory insight can streamline our support for your therapeutic.
About the event
TIDES USA is a leading conference focused on oligonucleotide, peptide, mRNA, and other advanced therapeutics, covering discovery, preclinical and clinical development, CMC, manufacturing, analytical, regulatory, and quality considerations.
BioAgilytix supports these programs with integrated bioanalytical, and CMC analytical services designed to generate reliable data, reduce complexity, and support regulatory expectations across every phase of development. If you’re planning to connect with us at TIDES, here are a few common questions that may help you get the most out of the conversation.
What types of programs does BioAgilytix typically support?
We work with teams developing oligonucleotide, peptide, mRNA, and other complex biologics across preclinical, clinical, and commercialization stages.
Can you support both bioanalytical and CMC analytical needs?
Yes. Many teams come to us when those two areas start to overlap. We support both, which helps reduce handoffs and keeps methods and data consistent as programs move forward.
When is the right time to engage with BioAgilytix?
Earlier than most teams think. Whether you’re still defining your analytical approach or preparing for method validation, early alignment can help avoid rework later.
What should I bring to a meeting at TIDES?
You don’t need anything formal. Most conversations start with a quick overview of your program, where you are in development, and where you’re running into challenges. From there, we can talk through options.
Do you support global programs?
Yes. Our teams operate across the U.S., Europe, and Australia with harmonized processes, which helps support programs that need consistent data and scalable capacity across regions.
Schedule a meeting with our experts on site
© Copyright 2026 BioAgilytix Labs. All rights reserved.
